Intravenous Infusions (XGHA:IIL) Interest Expense : GHS Mil (TTM As of . 20)

View and export this data going back to 2015. Start your Free Trial

What is Intravenous Infusions Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Intravenous Infusions's interest expense for the six months ended in . 20 was GHS 0.00 Mil. Intravenous Infusions does not have enough years/quarters to calculate its interest expense for the trailing twelve months (TTM) ended in . 20.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Intravenous Infusions's Operating Income for the six months ended in . 20 was GHS 0.00 Mil. Intravenous Infusions's Interest Expense for the six months ended in . 20 was GHS 0.00 Mil. Intravenous Infusions did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Intravenous Infusions Interest Expense Historical Data

The historical data trend for Intravenous Infusions's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intravenous Infusions Interest Expense Chart

Intravenous Infusions Annual Data

Trend

Interest Expense

Intravenous Infusions Semi-Annual Data

Interest Expense

Intravenous Infusions Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Intravenous Infusions (XGHA:IIL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Intravenous Infusions's Interest Expense for the six months ended in . 20 was GHS0.00 Mil. Its Operating Income for the six months ended in . 20 was GHS0.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in . 20 was GHS0.00 Mil.

Intravenous Infusions's Interest Coverage for the quarter that ended in . 20 is calculated as

Intravenous Infusions had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Intravenous Infusions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intravenous Infusions Ltd (XGHA:IIL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA

Website

https://www.iil.com.gh

Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.